Previous 10 | Next 10 |
home / stock / otskf / otskf news
2023-08-24 06:59:36 ET More on Medtronic Medtronic plc ( MDT ) Q1 2024 Earnings Call Transcript Medtronic plc 2024 Q1 - Results - Earnings Call Presentation Medtronic: Dark Clouds Are Clearing - Outperformance Ahead Medtronic: MiniMed 780G Could Inspire G...
2023-07-31 11:41:57 ET Otsuka Holdings Co., Ltd. press release ( OTCPK:OTSKF ): Q1 GAAP EPS of ¥189.06. Revenue of ¥947.54B (+16.4% Y/Y). For further details see: Otsuka Holdings Co., Ltd. GAAP EPS of ¥189.06, revenue of ¥947.54B
2023-05-12 05:35:59 ET Otsuka Holdings press release ( OTCPK:OTSKF ): Q1 GAAP EPS of ¥113.18. Revenue of ¥448.34B (+17.9% Y/Y). Forecast of Consolidated Financial Results for the Fiscal Year Ending December 31, 2023 : Revenue of ¥1,80...
2023-05-11 16:18:07 ET Summary BioXcel Therapeutics, Inc. is currently in exciting times, awaiting very important clinical trial results in the coming weeks. The recently released BioXcel Therapeutics first-quarter results provided a low revenue figure for IGALMI, however, the mar...
2023-05-11 05:56:21 ET The U.S. Food and Drug Administration (FDA) approved the expanded use of H. Lundbeck ( OTCPK:HLBBF ) ( OTCPK:HLUBF ) and Otsuka's ( OTCPK:OTSKY ) ( OTCPK:OTSKF ) medicine Rexulti (brexpiprazole) to treat agitation associated with dementia due to Alzh...
2023-04-13 15:36:07 ET German biotech Atai Life Sciences ( NASDAQ: ATAI ) added 12% Thursday after announcing investigators have dosed the first participant in a Phase 1 study for PCN-101, a candidate targeted at treatment-resistant depression (TRD). Atai ( ATAI ) comp...
2023-03-29 17:43:48 ET The US FDA has scheduled an advisory committee meeting to evaluate an application from Otsuka ( OTCPK:OTSKF ) and H. Lundbeck ( OTCPK:HLBBF ) to expand the indication for Rexulti (brexipiprazole) to include Alzheimer's disease agitation. The Psy...
Otsuka Holdings Co., Ltd. ( OTCPK:OTSKF ): FY GAAP EPS of ¥246.99. Revenue of ¥1.74B (+16.8% Y/Y). For further details see: Otsuka Holdings Co., Ltd. GAAP EPS of ¥246.99, revenue of ¥1.74B
Summary Vera Therapeutics has released an updated interim PP analysis on the phase 2b ORIGIN trial. The updated data excluded 14 patients who had some degree of a trial protocol violation, further enriching the data. The PP data was better than ITT data, where 36 weeks of data of th...
Summary Vera’s phase 2b ORIGIN data was underwhelming with lower than expected proteinuria reduction ~31% even at 9 months. We believe Atacicept’s commercial opportunity in IgAN is questionable due to the high degree of competition from KDNY, Otsuka, and Remegen. VERA ...
News, Short Squeeze, Breakout and More Instantly...
Otsuka Holdings Co. Ltd. Company Name:
OTSKF Stock Symbol:
OTCMKTS Market:
Tuesday, IGC Pharma Inc (NYSE:IGC) released interim data from its Phase 2 clinical trial of IGC-AD1 for agitation in dementia associ...
Wednesday, IGC Pharma Inc (NYSE:IGC) announced the results of an interim analysis of its ongoing Phase 2 trial of IGC-AD1 for Agitation i...
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety Psychedelics biotech Cybin (NYSE: CYBN) and UK-bas...